Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Medicines and Healthcare products Regulatory Agency (MHRA) has allowed Azellon to initiate a Phase I clinical trial in the UK, following the successful process development and validation work performed by Angel Biotechnology on behalf of Azellon.
Subscribe to our email newsletter
The trial will assess patients with meniscal tears (injury to cartilage tissues in the knee joint).
In the trial, the company plans to treat patients with a cell bandage product seeded with the patient’s own, expanded, stem cells.
Angel chief operating officer Gordon Sherriff said they are delighted that the work performed by Angel for Azellon has assisted them with their successful submission to the MHRA to conduct Phase 1 clinical trials in the UK.
"Angel were able to apply their technical and regulatory expertise to Azellon’s ground breaking product process to facilitate and ease their route to clinic," Sherriff said.